Comprehensive Characterization Strategies For Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) offer a highly targeted approach to therapy, but their promise depends on understanding the complex relationships between antibodies, linkers, and payloads. As ADC development expands beyond oncology to include therapeutic proteins and oligonucleotides, thorough characterization is becoming increasingly important for ensuring product quality, safety, and efficacy. Advanced analytical strategies can help connect molecular structure to biological function, revealing how critical attributes influence performance and mechanism of action. Insights gained during characterization also play a key role in identifying the critical quality attributes (CQAs) that matter most for development and manufacturing. A case study examining the impact of PEG linker length demonstrates how seemingly small design changes can affect ADC structure, target binding, and overall activity.

Explore the science behind ADC characterization and the analytical approaches that support more informed development decisions.